Addex ADX10059 monotherapy is effective on GERD symptoms in phase IIb trial
Tuesday, November 17, 2009 18:00 IST Geneva, Switzerland
Addex Pharmaceuticals, the allosteric modulation company, announced that it achieved statistically significant efficacy on the primary endpoint, increasing the number of symptom free days in the phase-IIb trial of ADX10059